<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561896</url>
  </required_header>
  <id_info>
    <org_study_id>IOSI-RTO-001</org_study_id>
    <nct_id>NCT03561896</nct_id>
  </id_info>
  <brief_title>Hypofractionated Brain Radiationcavity</brief_title>
  <official_title>Stereotactic Radiosurgery or Hypofractionated Image-Guided Radiotherapy to the Surgical Cavity After Resection of Brain Metastases: a Multicenter, Single Arm, Open-label, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncology Institute of Southern Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncology Institute of Southern Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after
      metastasectomy in cancer patients with brain metastases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with limited number of brain metastases from solid tumors are at high risk of local
      recurrence after surgical removal of the tumor mass. The standard Whole-brain radiotherapy
      (WBRT) demonstrated to reduce the risk of recurrence without improving survival. At the same
      time WBRT have substantial acute and late toxicity. Preliminary experiences with Stereotactic
      radiosurgery or hypofractionated radiotherapy of the resection cavity indicate promising
      local control and good tolerance. This attitude was only partially explored in prospective
      trials. In this research patients with limited number of brain metastases and controlled
      systemic disease will be treated, with such a stereotactic irradiation, at the same time with
      evaluation of the local control (Primary endpoint) by repeated MRI and of quality of life,
      neurologic functionning (with a battery of thsts, e.g. MMSE, QLQ-C30, EORTC BN-20) as well as
      overall survival as secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluate the recurrence probability in the surgical cavity after radiotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of surviving patients at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to systemic progression</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with progression of disease in any location other than the brain, according to CTCAE Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neurological progression</measure>
    <time_frame>1 year</time_frame>
    <description>Time to neurological deterioration (objective neurological examination and MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the quality of life through questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain Metastases, Adult</condition>
  <condition>Cancer Brain</condition>
  <arm_group>
    <arm_group_label>IGRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stereotactic Radiosurgery of the resection cavity (SRS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IGRT</intervention_name>
    <description>Image-Guided Radiation Therapy</description>
    <arm_group_label>IGRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SRS</intervention_name>
    <description>stereotactic radiation therapy</description>
    <arm_group_label>SRS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patient underwent surgery for single brain metastasis arising from solid neoplasia
             (lung, breast, melanoma, kidney, colorectal), with initial histological diagnosis, or
             selected cases with a resected lesion and a further non-resected lesion (from 1 to 2
             lesions), treatable with SRS / IGRT of the surgical cavity

          -  Patient ≥ 18 years

          -  Willngness to participate in the study, written informed consent

          -  Performance Status according to WHO 0-I

          -  Good general conditions and organ function

          -  Newly diagnosed chemotherapy-naïve disease or controlled systemic disease

          -  Good bone marrow, renal and hepatic function

          -  Stable steroid dose or reduced for at least 5 days

        Exclusion Criteria:

          -  History of previous brain irradiation

          -  Pregnancy or breastfeeding

          -  Histological diagnosis other than lung, breast, melanoma, kidney and colorectal
             malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianfranco A Pesce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IOSI, Bellinzona, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gianfranco A Pesce, MD</last_name>
    <phone>+41918119253</phone>
    <email>GianfrancoAngelo.pesce@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Che N Azinwi, MD</last_name>
    <phone>+41918118932</phone>
    <email>NgwaChe.Azinwi@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O.U. Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Umberto Ricardi, MD</last_name>
      <phone>39 011 6336626</phone>
      <email>uricardi@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <state>Ticino</state>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfranco A Pesce, MD</last_name>
      <phone>+41 (0)91 8118673</phone>
      <email>GianfrancoAngelo.pesce@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Gross, MD</last_name>
      <phone>+41 (0)61 2654945</phone>
      <email>markus.gross@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelyn Herrmann, MD</last_name>
      <phone>+41 (0)31 6322632</phone>
      <email>evelyn.herrmann@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Zwahlen, MD</last_name>
      <phone>+41 (0)52 266 26 45</phone>
      <email>daniel.zwahlen@ksw.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zürich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hansjörg Vees, MD</last_name>
      <phone>+41 (0)44 3872550</phone>
      <email>hansjoerg.vees@hirslanden.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oncology Institute of Southern Switzerland</investigator_affiliation>
    <investigator_full_name>Gianfranco Angelo Pesce</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Radation therapy</keyword>
  <keyword>sterotactic radiosurgery</keyword>
  <keyword>quality of life</keyword>
  <keyword>solid cancer</keyword>
  <keyword>palliation</keyword>
  <keyword>neurologic functionning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

